Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 23, Issue 3 (May 2021) 23, 231–235; 10.4103/aja.aja_49_20

Developing a coordinate-based strategy to support cognitive targeted prostate biopsies and correlative spatial-histopathological outcome analysis

Keiran D Clement1, Lizzy Day2, Helen Rooney1, Matt Neilson3, Fiona Birrell1, Mark Salji1,3,4, Elizabeth Norman1, Ross Clark2, Amit Patel5, John Morrison5, Hing Y Leung1,3,4

1 Department of Urology, Queen Elizabeth University Hospital, 1345 Govan Rd, Glasgow G51 4TF, UK
2 Department of Urology, Ayr University Hospital, Dalmellington Rd, Ayr KA6 6DX, UK
3 CRUK Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
4 Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1BD, UK
5 Department of Radiology, NHS Greater Glasgow and Clyde, Glasgow G51 4TF, UK

Correspondence: Dr. HY Leung (h.leung@beatson.gla.ac.uk)

Date of Submission 20-Jan-2020 Date of Acceptance 28-Jun-2020 Date of Web Publication 24-Nov-2020

Abstract

Lack of investment for magnetic resonance (MR) fusion systems is an obstacle to deliver targeted prostate biopsies within the prostate cancer diagnostic pathway. We developed a coordinate-based method to support cognitive targeted prostate biopsies and then performed an audit on cancer detection and the location of lesions. In each patient, the prostate is considered as two separate hemiprostates, and each hemiprostate is divided into 4 × 4 × 4 units. Each unit is therefore defined by a three-dimensional coordinate. We prospectively applied our coordinates approach to target 106 prostatic lesions in 93 men. Among 45 (of 106; 42.5%) lesions positive for cancer, 27 lesions (60.0%) harbored clinically significant disease. PSA density was significantly higher in patients with proven cancer (median: 0.264 ng ml−2) when compared to the noncancer group (median: 0.145 ng ml−2; P = 0.003, Wilcoxon rank-sum test). Lesions with Prostate Imaging-Reporting and Data System (PIRADS) score of 5 were found to have a cancer incidence of 65.2%, while PIRADS 4 and 3 lesions have a lower risk of cancer detection, as expected, at 37.3% and 31.3%, respectively. The probability of a lesion being cancerous in our series significantly decreases as we go from the “apex-to-base” dimension (odds ratio [OR]: 2.62, 95% confidence interval [CI]: 1.55–4.44, P = 0.00034). Our analysis also indicates that the probability of cancer decreases as the prostate volume increases (OR: 1.03, 95% CI: 1.01–1.05, P = 0.00327). Based on this feasibility study, the use of coordinates to guide cognitive targeted prostate biopsies warrants future validation study in additional centers.

Keywords: cognitive targeted prostate biopsies; coordinates; magnetic resonance imaging; prostate cancer

Full Text | PDF |

 
Browse:  666
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved